Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders
Abstract
Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.
Claims
exact text as granted — not AI-modified1 - 4 . (canceled)
5 . A nutritional supplement for eye health, comprising:
a capsule or tablet for oral ingestion that includes a composition comprising
(a) at least 0.5 mg of zeaxanthin, the zeaxanthin being present in the 3R-3R′ stereoisomer form and is substantially free of meso-zeaxanthin stereoisomers,
(b) zinc in an amount that does not exceed 40 mg,
(c) vitamin E, and
(d) vitamin C.
6 . The nutritional supplement of claim 5 , wherein the composition further includes omega-3 fatty acids.
7 . The nutritional supplement of claim 6 , wherein the composition further includes a lipoic acid
8 . The nutritional supplement of claim 7 , wherein the composition further includes lutein.
9 . The nutritional supplement of claim 5 , wherein the composition further includes lutein.
10 . The nutritional supplement of claim 9 , wherein the composition further includes omega-3 fatty acids
11 . The nutritional supplement of claim 9 , wherein the composition further includes mixed tocopherols.
12 . The nutritional supplement of claim 5 , wherein vitamin C is in the form of ascorbic acid.
13 . The nutritional supplement of claim 5 , wherein the capsule or table provides a daily dosage of the ingredients to the user that is released over a span of at least 3 hours following the oral ingestion.
14 . The nutritional supplement of claim 5 , wherein zeaxanthin is present in an amount of at least 10 milligrams.
15 . The nutritional supplement of claim 5 , wherein the composition contains an oily carrier material to enhance the uptake and bioavailability of the zeaxanthin.
16 . The nutritional supplement of claim 5 , wherein the composition further comprises at least one of taurine, carnitine and carnosine.
17 . A nutritional supplement for eye health, comprising:
a capsule for oral ingestion that includes a composition comprising
(a) an oily carrier material
(b) at least 0.5 mg of zeaxanthin, the zeaxanthin being present in the 3R-3R′ stereoisomer form and is substantially free of meso-zeaxanthin stereoisomers,
(b) zinc in an amount that does not exceed 40 mg,
(c) vitamin E, and
(d) vitamin C in the form of ascorbic acid.
18 . The nutritional supplement of claim 17 , wherein the composition further includes omega-3 fatty acids.
19 . The nutritional supplement of claim 18 , wherein the omega-3 fatty acids include docosa-hexaenoic acid (DHA) and eicosa-pentaenoic acid (EPA).
20 . The nutritional supplement of claim 17 , wherein the composition further includes a lipoic acid.
21 . The nutritional supplement of claim 17 , wherein the oily carrier material enhances the uptake and bioavailability of the zeaxanthin.
22 . The nutritional supplement of claim 17 , wherein the composition further includes lutein.
23 . The nutritional supplement of claim 17 , wherein the capsule provides a daily dosage of the ingredients to the user that is released over a span of at least 3 hours following the oral ingestion.
24 . A nutritional supplement for eye health, comprising:
a capsule for oral ingestion that includes a composition comprising
(a) omega-3 fatty acids including docosa-hexaenoic acid (DHA) and eicosa-pentaenoic acid (EPA),
(b) at least 0.5 mg of zeaxanthin, the zeaxanthin being present in the 3R-3R′ stereoisomer form and is substantially free of meso-zeaxanthin stereoisomers,
(c) zinc in an amount that does not exceed 40 mg,
(d) vitamin E, and
(e) vitamin C in the form of ascorbic acid.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.